Antibody Therapy of Cancer

Antibody marks the cancer cell and makes it easier for the immune system to find. The monoclonal antibody drug rituximab (Rituxan) attaches to a specific protein (CD20) found only on B cells, one type of white blood cell. Certain types of lymphomas arise from these same B cells. Monoclonal antibodies can also function by attenuating hyperactive growth signals neo angiogenesis. A monoclonal antibody can be conjugated to a radioactive particle that will ensure directed delivery to the cancer cell and slow and long release of the radiation, hence maximizing chances of positive outcome and minimizing non-specific damaging exposure to radiation.

  • Immuno Stimulatory Monoclonal Antibodies for Cancer Therapy
  • Clinical Practice on Current Monoclonal Antibodies Cancer Therapies
  • Hybridoma Technology for Production of Monoclonal Antibodies
  • Radiation Induced Immunogenic Modulation to Enhance T-Cell and Monoclonal Antibody Therapy of Cancer
  • Impact of Epigenetic Changes on Cervical Cancer Progression
  • Skin Cancer Immunology: Profiling the Inflammatory Response

Related Conference of Antibody Therapy of Cancer

April 04-05, 2024

38th International Conference on Immunology

Madrid, Spain
May 23-24, 2024

18th International Conference on European Immunology

Zurich, Switzerland

Antibody Therapy of Cancer Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in